Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
20.46 AUD | -5.45% | -14.64% | -18.06% |
May. 28 | Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call | |
May. 27 | Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.06% | 1.83B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals' Partner Secures US FDA Approval for Rett Syndrome Treatment